PDF icon PDF herunterladen
Am J Perinatol 2024; 41(S 01): e2941-e2951
DOI: 10.1055/a-2183-9013
Original Article

Interpersonal Influences on the Choice to Treat Nausea during Pregnancy with Medication or Cannabis

Amanda H. Mercer
1   Counselor Education Department, Portland State University, Portland, Oregon
,
Katherine E. MacDuffie
2   Department of Pediatrics, Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research Institute, University of Washington, Seattle, Washington
,
Elliott M. Weiss 
2   Department of Pediatrics, Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research Institute, University of Washington, Seattle, Washington
,
Allegra Johnson
3   Department of Radiology, University of Washington, Seattle, Washington
,
Stephen R. Dager
3   Department of Radiology, University of Washington, Seattle, Washington
,
Natalia Kleinhans
3   Department of Radiology, University of Washington, Seattle, Washington
› Institutsangaben
Funding This study was supported by the Foundation for the National Institutes of Health (5R21DA046696-02 to N.K. and S.R.D); Seattle Children's Research Institute; Treuman Katz Center for Pediatric Bioethics.
› Weitere Informationen
Auch verfügbar aufeRefHebammen
   Lizenzen und Reprints
Preview

Abstract

Objective This study aimed to better understand the interpersonal influences on a pregnant individual's decision of how to treat nausea and vomiting during pregnancy using a qualitative approach.

Study Design A semistructured interview guide was developed to assess pregnancy symptoms, decision-making regarding treating nausea, and interpersonal influences on treatment decisions. Interviews were conducted with 17 individuals enrolled in a neuroimaging and behavioral study of prenatal exposure to cannabis who used medication and/or cannabis to treat symptoms associated with pregnancy.

Results Interviews revealed four groups of stakeholders who influenced participant decision-making: medical providers, partners, family, and friends. Influence was categorized as either positive, negative, neutral, or absent (if not discussed or participant chose not to disclose). Those in the medication group reported only positive or neutral feedback from friends, family, partners, and providers. In contrast, the cannabis group participants reported positive feedback from friends, mixed feedback from family and partners, and negative feedback from providers, which was often felt to be stigmatizing. Many in the cannabis group also reported varying feedback from different medical providers. While the cannabis group frequently reported eliciting feedback from friends, family, and partners, the medication group often did not.

Conclusion Medication group participants reported entirely positive feedback from providers and often did not mention any feedback at all from partners, family, and friends. Cannabis group participants reported much more varied feedback, both positive and negative, from a variety of interpersonal contacts and sometimes decided to conceal their treatment choice after receiving or fearing negative feedback. We recommend further research into the health outcomes of pregnant patients who chose not to discuss their treatment decisions with providers, family, partners, or friends. We also suggest further study of possible reasons behind a lack of disclosure, including fear of stigma and/or legal consequences.

Key Points

  • Providers, partners, family, friends gave feedback.

  • Medication group got positive feedback.

  • Cannabis group stigmatized by providers.

  • Cannabis group got mixed feedback.

Keywords

marijuana - cannabis - antinausea medication - pregnancy - nausea


Publikationsverlauf

Eingereicht: 31. Dezember 2022

Angenommen: 26. September 2023

Accepted Manuscript online:
29. September 2023

Artikel online veröffentlicht:
27. Oktober 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA